STOCK TITAN
  1. Home
  2. News
  3. DRRX

Durect Corp - DRRX STOCK NEWS

Welcome to our dedicated news page for Durect (Ticker: DRRX), a resource for investors and traders seeking the latest updates and insights on Durect.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Durect's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Durect's position in the market.

News
DURECT Corporation Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
Rhea-AI Summary
DURECT (DRRX) reports financial results for Q4 and full year 2023, along with a business update. Ongoing communication with FDA for Larsucosterol in Alcohol-Associated Hepatitis. Webcast of earnings call on March 27th.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.7%
Tags
earnings
-
News
DURECT Corporation to Announce Fourth Quarter and Full Year 2023 Financial Results and Provide a Business Update
Rhea-AI Summary
DURECT (Nasdaq: DRRX) will report its Q4 and full year 2023 financial results on March 27, 2024. The company focuses on epigenetic therapies for serious conditions like acute organ injury and cancer. Investors can join a conference call and webcast for updates.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.34%
Tags
earnings
-
News
DURECT and Charles River Laboratories Enter into Co-Marketing and Collaboration Agreement for ALZET® Product Line in U.S. and Canada
Rhea-AI Summary
DURECT Corporation (Nasdaq: DRRX) partners with Charles River Laboratories for a co-marketing and collaboration agreement to promote ALZET Osmotic Pumps Portfolio and Associated Product Line in the U.S. and Canada. The partnership aims to jointly market and commercialize the product line over a multi-year period, leveraging Charles River's expertise in drug discovery and non-clinical development solutions.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.94%
Tags
none
News
DURECT Corporation to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference
Rhea-AI Summary
DURECT Corporation (Nasdaq: DRRX) will present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference, virtually, on February 14, 2024. The company's President and CEO, James E. Brown, will be presenting. The webcast link is available on DURECT's homepage. Management will also be available for one-on-one meetings with institutional investors during the conference.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.04%
Tags
conferences
-
News
DURECT Corporation Reports Third Quarter 2023 Financial Results and Business Update
Rhea-AI Summary
DURECT Corporation (Nasdaq: DRRX) reported topline data from the AHFIRM trial, showing a promising efficacy signal in favor of larsucosterol in reducing mortality in alcohol-associated hepatitis (AH) patients. The company plans to discuss the trial results with the FDA in the first quarter of 2024 and potentially design a Phase 3 trial using mortality as the primary endpoint. Financially, total revenues were $1.7 million, with a net loss of $3.0 million for the three months ended September 30, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.89%
Tags
earnings
-
News
DURECT Corporation to Announce Third Quarter 2023 Financial Results and Provide a Business Update
Rhea-AI Summary
DURECT Corporation (Nasdaq: DRRX) to Report Q3 2023 Financial Results on November 13, 2023. The company will host a conference call and webcast to discuss financial results and provide a corporate update. Details for the call and webcast are provided in the press release.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.02%
Tags
earnings
News
DURECT Corporation Announces Topline Results from Phase 2b AHFIRM Trial of Larsucosterol in Alcohol-Associated Hepatitis with Promising Effect on Mortality
Rhea-AI Summary
DURECT Corporation (Nasdaq: DRRX) announces positive topline results from its AHFIRM trial, demonstrating a compelling reduction in 90-day mortality for larsucosterol in patients with severe alcohol-associated hepatitis. The 30 mg and 90 mg doses showed a 41% and 35% reduction in mortality, respectively, compared to standard of care (SOC). More pronounced effects were observed in the U.S. trial population, with a 57% and 58% reduction in mortality for the 30 mg and 90 mg doses, respectively.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-79.46%
Tags
clinical trial
-
News
DURECT Corporation Announces Last Patient Last Visit in Phase 2b AHFIRM Trial of Larsucosterol in Alcohol-Associated Hepatitis
Rhea-AI Summary
DURECT plans to report topline data from AHFIRM trial in Q4 2023. Positive outcome may lead to FDA approval for larsucosterol as the first treatment for alcohol-associated hepatitis (AH).
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.35%
Tags
clinical trial
-
News
DURECT Corporation Announces Presentations in Upcoming Investor Conferences
Rhea-AI Summary
DURECT Corporation will present at H.C. Wainwright 25th Annual Global Investment Conference on September 11, 2023, and at Cantor Fitzgerald Annual Global Healthcare Conference on September 27, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences
News
DURECT Corporation Reports Second Quarter 2023 Financial Results and Business Update
Rhea-AI Summary
DURECT Corporation (Nasdaq: DRRX) Announces Q2 2023 Financial Results and Corporate Update
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.85%
Tags
earnings
Stock DRRX logo
Durect Corp

Nasdaq:DRRX

DRRX Rankings

#5008 Ranked by Market Cap
#5039 Ranked by Stock Gains
N/A Ranked by Dividends

DRRX Stock Data

23.77M
29.66M
5.97%
22.56%
3.32%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US
Cupertino

About DRRX

durect is a specialty pharmaceuticals company with expertise in drug discovery, drug delivery and drug development, applying those skills primarily to therapeutics in the fields of pain management, acute organ injury and metabolic diseases. durect’s proprietary oral, transdermal and injectable depot delivery technologies enable new indications and superior clinical/commercial attributes such as improved abuse deterrence, convenience, adherence, efficacy and safety for small molecule and biologic drugs. late stage development programs of this nature include remoxy® and posidur™. durect’s epigenomic regulator program includes the lead molecule dur-928 in phase 1 clinical testing. dur-928 is an endogenous small molecule that is an epigenomic modulator of cellular activities involved in lipid homeostasis, metabolic disease, inflammation and cell survival. for more information, please visit www.durect.com. we also manufacture and sell two commercial product lines: • alzet® osmotic pumps use